45 results
6-K
EX-99.1
CMMB
Chemomab Therapeutics Ltd
3 Jan 24
Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary
7:00am
in the PSC trial ahead of projections, as well as the commitment of the many patients and advocacy organizations who contributed to the success of the study
424B5
znw ipc35
25 Apr 22
Prospectus supplement for primary offering
4:19pm
8-K
EX-99.1
jueybxb
9 Mar 22
Chemomab Therapeutics Announces Fourth Quarter and Year End 2021 Financial
6:05am
8-K
EX-99.1
kk4bo
3 Dec 21
Chemomab Therapeutics Names David M. Weiner, MD as Interim Chief Medical Officer
8:05am
8-K
EX-99.1
827758er697byk
8 Nov 21
Departure of Directors or Certain Officers
7:35am
S-3
EX-10.3
cml5z7h1io0uox06
15 Apr 21
Shelf registration
4:03pm
8-K/A
EX-99.1
5ybrshvin402618z1
19 Mar 21
Financial Statements and Exhibits
8:51am
8-K
EX-3.1
ephvh7oa86fk8pz z06
17 Mar 21
Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing
12:00am
S-4
EX-3.1
fgq9jsp9sblz 0ii
13 Jan 21
Registration of securities issued in business combination transactions
9:30am
S-4
EX-2.7
usmq0ek1y9n6l45z
13 Jan 21
Registration of securities issued in business combination transactions
9:30am
S-4
EX-2.1
b4jv8usu8tvg826
13 Jan 21
Registration of securities issued in business combination transactions
9:30am